Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 12, 2007. The report details a share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 3,100,000 Ordinary shares
- Purchase Price: 1,282.39 pence per share
- Treasury Shares Held: 439,889,158 shares (7.88% of total voting rights)
- Shares in Issue: 5,584,780,317 shares (excluding Treasury shares)
Material Changes
The primary material change is the reduction of outstanding shares through the acquisition of 3,100,000 shares on October 12, 2007. Consequently, the total number of shares held in Treasury increased to 439,889,158, representing 7.88% of the Company's total voting rights.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (5,584,780,317) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (439,889,158) and its impact on total voting rights (7.88%).
- Note that this transaction was executed at a specific price of 1,282.39 pence per share.